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ABSTRACT 
Background-Malaria remains a threat to millions of children despite the recent advances recorded in the fight against the 
disease which remain the 3rd largest killer of children below the age of 5 years in endemic regions. Drug resistant plasmodium 
species continues to limit the fight against malaria, while the spread of fake and substandard antimalarial drugs has been 
recognized as a major problem across Africa because of its association with drug resistant parasite. We aim to find out the 
prescription pattern of chloroquine among nurses in South-West Nigeria and perception of artemisinin-based combination 
therapy (ACT).  
Design and methods-About 180 pre-tested questionnaires were administered to randomly selected nurses out of which 155 were 
sufficiently completed and suitable for analysis. Results-Majority (56.1%) still have confidence in the efficacy of CQ which was 
still being prescribed by 45.2% of the respondents. CQ was mostly prescribed by those who had previous ACT treatment failure 
experience (54.3%) with their patients, P=0.03; as well as those who believe that ACT resistance malaria is now in circulation 
(44.3%). Fifty (32.3%) of our respondents claimed that they had come across fake and substandard ACT, from which 40.0% now 
prescribe CQ.  
Discussion-The high rate of CQ prescription in this study showed that many of the health workers were still resistant to the 
change in antimalarial treatment policy, which is related to unsatisfactory experience with ACT. Additional measures are 
urgently required to verify this experience so as to win the confidence of healthcare workers away from chloroquine.  
Key words- Artemisinin-based combination therapy (ACT), chloroquine, substandard antimalarial 
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RESUME : 
Contexte : Le paludisme reste une menace aux millions d’enfants en dépit des progrèsrécentsenregistrés dans la lutte contre la 
maladie et ce qui reste la troisième cause de décès des enfants de moins de 5 ans dansles régionsendémiques. Les espèces de 
plasmodium résistants aux médicaments continuent à limiter la lutte contre le paludisme, alors que  la dispersion des drogues 
anti paludismes contrefaits et non conformes a été reconnu comme un problème majeur à travers l’Afrique en raison son 
association avec parasite résistant aux médicaments. Nous nous efforçons de trouver le modèle de prescription de chloroquine 
parmi les infirmiers au Sud – Ouest du Nigeria et la perception de thérapiecombinée à base d’artemisinine (ACT). 
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Conception and Méthodes : Environ de 180 questionnairespré – testes ont été administrés aux infirmiers choisis au hasard dont 
155 ont été suffisamment complétés et appropries pour analyser. 
Résultats : La majorité (56,1%) ont encore confiance dans l’efficacité de CQ qui était encore prescrit par 45,2% des répondants. 
CQ était surtout prescrit par ceux qui ont eu une expérienceprécédente de l’échec du traitement de ACT (54,3%)avec leurs 
patients=0,03, et également ceux qui croient que la résistance du paludisme au ACT est maintenant en circulation (44,3%). 
Cinquante (32,3%) de notrerépondants ont maintenu qu’ils avaient  rencontré par hasard un ACT contrefait et non confirmé, 
desquels 40,0% prescrivent maintenant CQ. 
Discussion : Le taux élevé de prescription de CQ dans cette étude a montré que beaucoup de travailleurs de santéétaient encore 
résistants au changement de po ;itique de traitement antipaludique, qui est lié à l’expérience insatisfaisante avec ACT. 
Méthodessupplémentaires sont nécessaires de toute urgence pour vérifier cette expérience pour gagner la confiance des 
travailleurs de la sante de la chloroquine. 
Mots – clés : La thérapie à base d’artemisinine ; (ACT), Chloroquine antipaludique non conformé. 
INTRODUCTION 
Malaria is among the top 3 killers of children all over 
the world where it is estimated that more than 3 
billion people are at risk of infection. About 198 
million malaria cases with associated 584,000 deaths 
were estimated to have occurred all over the world in 
2013 (1). Malaria burden is heaviest in Africa where 
about 90% of all the death occurs, with 78% of such 
deaths in children below the age of 5 years. Malaria is 
also the 3rd on the list of top ten causes of death in 
Nigeria, and the country is said to incur malaria death 
than any other country in the world (2). The current 
malaria control strategy include the use of long 
lasting insecticide treated nets (LLITN), use of indoor 
residual insecticide spray (IRS), prompt diagnoses 
and treatment of cases with artemisinin bases 
combination therapy (ACT). Malaria control has been 
hampered by the development of resistance by 
mosquitoes to commonly used insecticides as well as 
development of resistance by plasmodium species to 
every antimalarial drug that has ever been deployed 
in malaria chemotherapy.  
Chloroquine (CQ) has been in the frontline of malaria 
treatment and control since it was first discovered in 
1934. It is also said to be the most successful 
antimalarial drug of all time (3,4). Resistance against 
CQ was believed to have emerged from South 
America (5) and South East Asia (6) from where it 
spread to West Africa and other countries of the 
world (7,8).  The reduced efficacy of CQ prompted the 
WHO to come up with the policy change in 
antimalarial chemotherapy whereby it was agreed 
that CQ should be substituted as the first line drug in 
countries where resistance is more that 25% threshold 
(9). 
Nigeria formally adopted policy change from CQ to 
ACT in 2004, and since then, there were many 
challenges from health care workers as well as 
patients in terms of compliance to the new treatment 
guidelines (1). 
The most recent WMR which showed that prevalence 
of malaria infection in Sub-Sahara Africa among the 
children aged 2-10 years fell from 26% in 2000 to 14% 
in 2013. And in Nigeria which has the largest number 
of global malaria death, under 5 mortality rate also 
reduced from 213 per 1,000 live birth in 1990 to 117 
per 1,000 live birth in 2013 (10). Against the 
background of this positive development, only about 
9-26% of children with malaria as at 2013 were treated 
with ACTs. Some of the reasons behind this was said 
to be due to the fact that many of the children did not 
seek treatment, while many of those who sort 
treatment were not given any antimalarial drug (1). 
A study conducted in 2013 on the use of ACT in 
Nigeria showed that CQ was still being used by about 
39% of the respondents while ACT was used by only 
about 13.6%.  The same study also revealed that 
nurses were the second most important group of 
health care workers that prescribe antimalarial drugs 
following doctors (11). A similar study conducted in 
Kenya showed that insufficient supply of ACT, cost 
and availability of inappropriate antimalarial such as 
amodiaquine were some of the reasons why 
healthcare workers still don’t comply with ACT 
treatment policy (12). Another possible reason why 
health care workers may still be having problem with 
the compliance to ACT treatment policy despite the 
fact that it has been in place for the past 10 years 
might be because many still have confidence in the 
older drugs. Presence of fake and substandard ACT in 
circulation may be associated with treatment failure 
which might cause health care workers to have 
diminished confidence and be tempted to fall back on 
the older drugs. A recent survey of fake antimalarial 
drugs in Nigeria showed that 6.8% of the ACT in 
circulation was substandard, while another 1.3% was 
already degraded.  About 1.2% of the circulating ACT 
was also found to be falsified (13). Fake and 
substandard antimalarial drugs, especially ACT, 
mostly find their way to Africa from Asian countries. 
In a study by Newton et al that investigated the rate of 
counterfeit antimalarial drugs en route to Africa from 
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Asia, fake drugs were found in 8 of the 11 countries 
sampled. Some of the unwholesome antimalarial 
drugs sampled included counterfeit artesunate that 
contains chloroquine, counterfeit dihydroartemisinin 
containing just acetaminophen, and counterfeit 
artemether-lumefantrine containing pyrimethamine 
(14). 
Several studies have shown that nurses are important 
part of the health care team involved in management 
of malaria in the community and are often involved in 
prescription of antimalarial drugs. They sometimes 
constitute the first point of contacts in malaria 
treatment at primary health care level (15,16,17). 
Despite the change in treatment policy, Onyeaso and 
Oluwole found out that Chloroquine was the most 
frequently prescribed antimalarial drug for malaria 
prophylaxis by primary healthcare providers in a 
study in Nigeria. The reason for this was said to 
include ease of availability, affordability and 
insufficient knowledge of healthcare providers 
regarding efficacy and resistance of antimalarial 
drugs (17). Study in Tanzania also showed that SP 
was not well received by the healthcare workers 
several years after it was substituted for CQ (18). 
Similar studies in Kenya and Ghana also showed that 
Health care workers were resistant to malaria 
treatment policy change in a similar way malaria 
seems to be resistant to the changed medication (19, 
20). The study in Kenya even showed that qualified 
healthcare workers (Doctors and Trained Nurses) 
were more likely to be less compliant with the new 
treatment policy.  Longitudinal study in Tanzanian 
where malaria treatment policy had been changed 2ce 
in a decade found out that healthcare workers 
compliance to the new antimalarial drugs worsens 
over time (21). It was suggested that this may be 
based on their routine experiences in the clinical 
management of patients whereby the healthcare 
workers may be the first to notice inadequate clinical 
response to treatment before the attention of other 
stakeholders is eventually drawn to it. 
Ability of malaria to develop resistance to ACT has 
never been in doubt; there are reports of resistance to 
ACT in South –East Asia, the same area where 
resistance to CQ was believed to have originated (21, 
22, 23). A recent publication from eastern part of 
Nigeria reported 3 cases of Plasmodium 
falciparum malaria that showed early treatment failure 
(ETF) to artemisinin-based combination therapy. All 
the 3 cases showed adequate clinical response when 
treated with quinine. The publishers suggested that 
the failure might as well be due to questionable 
quality of the ACT, but then other patients that were 
treated with the same batch of drug were said to have 
responded adequately (24). This study aimed at 
investigating the level of chloroquine prescription 
among nurses in South West in Nigeria as well the 
possible role their experience with the use of ACT 
might play. 
MATERIALS AND METHODS 
About 180 pre-tested questionnaires were 
administered to randomly selected nurses in Sagamu, 
South-West Nigeria between the month of March and 
May 2015 to access the level of confidence they still 
had in CQ. Nurses in both private and public health 
care facilities were targeted for this purpose. 
Informed consent were obtained from the participants 
who were also made to realize that the questions were 
meant for research purpose only, and that answers 
provided will be made confidential. One hundred and 
sixty nine of the questionnaires (94%) were retrieved 
out of which 155 were sufficiently completed and 
suitable for analysis. The questionnaires were entered 
into Excel spread sheet and later exported to PSPP 
GNU statistical software version 0.8.5 for analysis. 
Results were cross tabulated and chi square was used 
to test for degree of association between the variables. 
Associations were said to be significant when P value 
was found to be less than 0.05. 
RESULTS 
Most of our respondents (58%) practice in public 
hospitals while 25% practice in private hospitals, and 
the rest work at both settings (Figure 1). Seventy six 
(49%) of the respondents are younger than 30 years 
old while 67 (43%) have less than 5 year post basic 
qualification experience (Table 1). Majority (56.1%) 
still have confidence in the efficacy of CQ while 
another 18.1% were not sure whether the drug is no 
longer efficacious, P=0.01. Many of the nurses above 
40 years of age (69.1%) and majority of those who 
have between 11 to 20 years of post-qualification 
experience (71.4%) still have confidence in CQ 
efficacy P=0.001. Sixty three (40.7%) of the 
respondents have experienced ACT treatment failures 
with their patients during the course of their practice 
which were eventually treated with another 
antimalarial. Majority of those who still have 
confidence in the efficacy of CQ were those that have 









TABLE 1: ASSOCIATION BETWEEN CONFIDENCE IN EFFICACY OF CQ AND AGE, YEARS OF EXPERIENCE AND ACT 
TREATMENT FAILURE EXPERIENCE. 
 Confidence in the efficacy of CQ 
Yes (%) No(%) Not sure(%) Total(%) 
Age 
              <30 
              30-40 
              >40 






















Years of experience 
             <5 
             5-10 
             11-20 






















ACT  treatment failure 
experience 
                Yes 
                No 




























The younger nurses (30.1%) and those with less than 5 
years of experience (28.45%) had fewer experience 
with ACT treatment failure compared to the older 
and more experienced nurses. But the older and more 
experienced nurses were more sure of their 
perception of ACT treatment failure with only 2 
(4.8%) of those above 40 and only 1 (3.8%) of those 
with 11 to 20 years of experience in the not sure 
category. 
Our study showed that 70 (45.2%) of our respondents 
still prescribe CQ (P=0.02). It was also discovered that 
CQ was mostly prescribed by those who had previous 
ACT treatment failure experience (54.3%) with their 
patients, P=0.03; as well as those who believe that 
ACT resistance malaria is now in circulation (44.3%). 
Fifty (32.3%) of the nurses admitted that they had 
come across self-recognized fake ACT before (Figure 
2), out of which 40% now prescribe CQ, (Table 3).  
 
TABLE 2: RELATIONSHIP BETWEEN ACT TREATMENT FAILURE EXPERIENCE AND AGE AS WELL AS YEARS OF 
EXPERIENCE OF RESPONDENTS 
 ACT  treatment failure  experience 
Yes (%) No (%) Not sure (%) Total (%) 
Age 
               <30 
              30-40 






















Years of experience 
                <5 
                5-10 
              11-20 



























TABLE 3: PATTERN OF CHLOROQUINE PRESCRIPTION AMONG RESPONDENTS.
 Still prescribe  CQ to patients
Yes (%) 
Age 
                    <30 
                     30-40 
                      >40 
                      Total  
   P=0.02 
 
Years of experience 
                       <5 
                        5-10 
                      11-20 
                      >20 
                     Total 
     P=0.57 
 
ACT  treatment failure 
experience 
                  Yes 
                  No 
                  Not sure 
    P=0.01 
 
Encounter fake ACT 
                  Yes 
                  No 
                  Not sure 
     P=0.03 
 
ACT resistance is in circulation 
                   Yes 
                   No 
                   Not sure 





































FIGURE 1.PLACE OF PRACTICE.                                                                                                  
(1) PUBLIC HOSPITAL = 90 (58%), (2) PRIVATE 
HOSPITAL= 38 (25%), (3) BOTH PUBLIC AND 



















































































                                                                                    
FIGURE 2:  HAD COME ACROSS RECOGNIZED 
FAKE ACT BEFORE?                                                                                                             
(1) YES =50 (32.3%), (2) NO= 71 (45.8%), (3) NOT SURE 
=34 (21.9%) 
DISCUSSION 
The WHO recommends regular antimalarial
treatment efficacy trials so as to keep an eye on 
impending Plasmodium resistance. Clinical efficacy 
trials with standardized protocol are the best way of 
doing this. In this study, we sampled the opinion of 















treatment and control, nurses, to find out their 
perception of ACT efficacy as well as the level of 
confidence they still have in chloroquine. 
The number of nurses who still prescribe CQ in this 
study is still high, 70(45.2%). This is similar to 
studies in Kenya and Tanzania which also found 
poor compliance with the new antimalarial 
treatment policy. The relationship between the 
confidence in the efficacy of CQ and its prescription 
rate with age and years of experience of our 
respondents may actually be related to the long 
years of experience they had with it, before it 
became a failed drug. Adherence to CQ by 
healthcare workers in similar Nigerian study was 
attributed to its cheaper price and ease of 
availability (17).   
The numbers of respondents who still have 
confidence in CQ suggest that the drug is not a 
100% failed drug. But then, is important to 
effectively educate healthcare workers about the 
rationale behind the policy change in the first place. 
It is important to let all stakeholders appreciate the 
fact that only 25% failure rate was what informed 
the change, and that some degree of treatment 
success is still expected, which does not warrant 
early return to its use. 
Perception of nurse’s ACT treatment failure as 
recorded in this study will need further 
investigation, especially when it is associated with 
CQ prescription. The recent claim of 3 cases of ACT 
treatment failure by Ajayi and Ukwaja (24) also 
supported this nurse’s suspicion.   High prevalence 
of this perception among the more experienced 
healthcare workers calls for concern because the 
impression can readily be transmitted to the 
younger ones who they are expected to instruct and 
mentor.  A similar study in Tanzania also found out 
that personal experience among healthcare worker 
including doctors, was responsible for poor 
adherence to new antimalarial treatment policy. 
The same study also showed that healthcare 
workers easily bring their experience to bear when 
prescribing drugs for their patients (21). 
Experience of our respondent’s with fake and 
substandard antimalarial drugs further suggests 
that the menace of unwholesome ACT is still a 
reasonable treat in Africa and this should be further 
investigated in a more formalized study. The issue 
of fake and substandard ACT calls for urgent 
remedial attention since it is found in this study to 
be associated with increased CQ prescription by 
health care workers. 
We will like to recommend that standard methods 
should be developed to evaluate and document the 
personal experience of healthcare workers 
regarding antimalarial treatment failure. Records 
from such data can serve as an adjunct to the 
standard clinical efficacy trial. When healthcare 
workers realize that their experience contributed to 
decision that lead to a change in treatment policy, 
they are more like to adhere to such a joint decision 
compare to when they perceive the policy emanated 
from a group of sponsored researchers alone.   
One limitation of our study is that there was no 
documented laboratory evidence of malaria in 
patients that were said to have experienced 
treatment failure with ACT by our respondents. But 
then this is also not sufficient to dismiss the claims 
of these respondents because most malaria cases in 
Africa are still being treated without laboratory 
evidence. 
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Significance for public health 
Despite the change in the malaria treatment policy 
in Nigeria over the last 10 years, our study showed 
that a large proportion of the healthcare workers 
still prescribe chloroquine. This practice was 
significantly associated with the believe that ACT 
resistance malaria is now in circulation as well as 
the experience of the workers with ACT treatment 
failure. Urgent measures have to be taken to 
investigate the believe of this group of healthcare 
workers so as to reinforce confidence in ACT in 
order to sustain the progress made so far in the 
fight against malaria. 
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